RAP-103 / Clarent Biopharma - LARVOL DELTA

RAP-103, a multi-chemokine receptor antagonist, displays anxiolytic-like effects and normalizes methamphetamine abstinence-induced behaviors in planarians. (PubMed, Physiol Behav) - "Maraviroc (1, 10 μM), a CCR5 antagonist, decreased light avoidance (like RAP-103) but reduced motility. RAP-103 (0.01, 0.1, 1 μM), administered during METH abstinence, counteracted METH-induced light avoidance but did not rescue METH-induced motility deficits. Our results with planarians show that RAP-103 displays anxiolytic-like and motor-enhancing effects and counteracts METH abstinence-induced behaviors, highlighting the potential of RAP-103 as a chemokine-based CNS therapeutic."

Journal • CCR2 • CCR8

RAP103-Pso: Safety and Efficacy of RAP-103 to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects (clinicaltrials.gov) - P2 | N=90 | Not yet recruiting | Sponsor: Clarent Biopharma, Inc.

HEOR • New P2 trial • Dermatology • Immunology • Psoriasis